X

HALO

Halozyme Q4 2025 Earnings Surge: Royalty Revenue Soars 52%

Halozyme Therapeutics Inc. (NASDAQ: HALO) hit record revenue. Full-year 2025 revenue reached $1.4 billion. So this is 38% growth year-over-year.…

Halozyme Therapeutics, Inc (HALO) Q4 2025 Earnings Call

Halozyme Therapeutics, Inc (NASDAQ: HALO) Q4 2025 Earnings Conference

Halozyme Therapeutics, Inc (HALO) Q4 2025 Earnings Announcement

Halozyme Therapeutics, Inc (NASDAQ: HALO) Q4 2025 Earnings Announcement

Halozyme Therapeutics, Inc (HALO) Q2 2025 Earnings Call Transcript

Halozyme Therapeutics, Inc (NASDAQ: HALO) Q2 2025 Earnings Call dated Aug. 05, 2025 Corporate Participants: Tram Bui — Head of…

Halozyme Therapeutics, Inc (HALO) Q3 2025 Earnings Call Transcript

Halozyme Therapeutics, Inc (NASDAQ: HALO) Q3 2025 Earnings Call dated Nov. 03, 2025 Corporate Participants: Tram Bui — Head of…

Halozyme Therapeutics, Inc (HALO) Q2 2022

Halozyme Therapeutics, Inc (NASDAQ: HALO) Q2 2022 Earnings Conference

Halozyme Therapeutics, inc (HALO) Q3 2021

Halozyme Therapeutics, inc (NASDAQ: HALO) Q3 2021 Earnings Conference

Halozyme Therapeutics, inc (HALO) Q2 2021

Halozyme Therapeutics, inc (NASDAQ: HALO) Q2 2021 Earnings Conference

Halozyme Therapeutics, inc (HALO) Halozyme Reports First Quarter 2021 Results

Halozyme Therapeutics, inc (NASDAQ: HALO) Q1 2021 Earnings Conference